Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/11026
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Van Wilder, Philippe | - |
dc.contributor.author | ZHU, Qi | - |
dc.contributor.author | VERAVERBEKE, Noel | - |
dc.date.accessioned | 2010-08-03T07:36:26Z | - |
dc.date.available | NO_RESTRICTION | - |
dc.date.available | 2010-08-03T07:36:26Z | - |
dc.date.issued | 2010 | - |
dc.identifier.citation | DRUG INFORMATION JOURNAL, 44 (3). p. 317-323 | - |
dc.identifier.issn | 0092-8615 | - |
dc.identifier.uri | http://hdl.handle.net/1942/11026 | - |
dc.description.abstract | The European Pharmaceutical Forum (EPF) issued "good practice" recommendations on the need to identify and reward valuable innovation. We investigated the compliance of the Belgian reimbursement procedure with the specific EPF recommendations by analyzing all 110 submissions for added therapeutic value (ATV) in the period 2002-2007. Prior to the reimbursement decision, a relative assessment of the therapeutic value was done with a binary outcome (ATV granted or refused). Overall, ATV was granted for 61 submissions (55%) or 10 compounds per year Because this number is similar to the number of new products with CDER priority review or with "important to major" therapeutic benefit granted by the French reimbursement authority, we expect that valuable innovation has been identified. A positive reimbursement decision was obtained in 76 cases (69%). Granting of ATV (P < .001) was the most significant factor affecting the reimbursement decision (OR and its 95% CI: 179 [5.5-58.3]), suggesting the Belgian reimbursement procedure also rewards value for innovative products as EPF recommends. Because more than 50% of the variance still remains unexplained, one cannot confirm or reject the impact of other factors (financial, economic, etc) possibly affecting the reimbursement decision. | - |
dc.description.sponsorship | Philippe Van Wilder and Noel Veraverbeke report no relevant relationships to disclose. Qi Zhu has disclosed that he has received grants/research support from the Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Hassell University. | - |
dc.language.iso | en | - |
dc.publisher | DRUG INFORMATION ASSOC | - |
dc.subject.other | Reimbursement; Innovation; Added value; Effectiveness; Pharmaceutical forum | - |
dc.subject.other | Reimbursement; Innovation; Added value; Effectiveness; Pharmaceutical forum | - |
dc.title | Identifying and Rewarding Pharmaceutical Innovation: Application in an EU Member State | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 323 | - |
dc.identifier.issue | 3 | - |
dc.identifier.spage | 317 | - |
dc.identifier.volume | 44 | - |
local.format.pages | 7 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | [Van Wilder, Philippe] RIZIV Natl Insurance Agcy Sickness & Disabil, Brussels, Belgium. [Zhu, Qi; Veraverbeke, Noel] Hasselt Univ, Ctr Stat, Diepenbeek, Belgium. philippe.smart@gmail.com | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.bibliographicCitation.oldjcat | A1 | - |
dc.identifier.isi | 000277585300013 | - |
item.contributor | Van Wilder, Philippe | - |
item.contributor | ZHU, Qi | - |
item.contributor | VERAVERBEKE, Noel | - |
item.fulltext | No Fulltext | - |
item.validation | ecoom 2011 | - |
item.fullcitation | Van Wilder, Philippe; ZHU, Qi & VERAVERBEKE, Noel (2010) Identifying and Rewarding Pharmaceutical Innovation: Application in an EU Member State. In: DRUG INFORMATION JOURNAL, 44 (3). p. 317-323. | - |
item.accessRights | Closed Access | - |
crisitem.journal.issn | 0092-8615 | - |
Appears in Collections: | Research publications |
WEB OF SCIENCETM
Citations
1
checked on May 2, 2024
Page view(s)
72
checked on Jul 18, 2023
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.